GRAND PHARMA (00512) proposes appointing Deloitte as the new auditor.
Grand Pharma (00512) announced that, to support the Group's overseas expansion strategy, the Board considers it an appropriate time to rotate the Company's external auditor.
GRAND PHARMA (00512) announces that, in order to support the Group's overseas expansion strategy, the Board considers that now is an appropriate time to rotate the Company's external auditor. Based on the recommendation of the Audit Committee of the Board, the Company proposes to terminate the appointment of the Company's current auditor, Kwan Wong Tan & Fong CPA Limited (Kwan Wong), as the auditor of the Company for the year ending 31 December 2026 (the Proposed Termination), and to appoint Deloitte Kwan Wong Tan & Fong CPA Limited (Deloitte) as the Company's new auditor for the year ending 31 December 2026 to fill the casual vacancy arising from the "Proposed Termination", and to hold office until the conclusion of the next annual general meeting of the Company (the Proposed Appointment, together with the "Proposed Termination", collectively the "Proposed Change of Auditor"). The Proposed Change of Auditor is subject to, among other things, the passing of the relevant resolution(s) by the extraordinary general meeting of the Company to be convened.
Related Articles
DOBOT (02432): Trustee purchases 50,000 shares under the H-share incentive plan.
US Stock Market Move | Optical communication concept stocks broadly declined; Nokia Oyj Sponsored ADR (NOK.US) fell over 9%.
CNBM (03323): Beijing New Building Materials Public (000786.SZ) reported a net profit attributable to shareholders of RMB 1.905 billion for the first three quarters, down 26.35% year on year.
DOBOT (02432): Trustee purchases 50,000 shares under the H-share incentive plan.
US Stock Market Move | Optical communication concept stocks broadly declined; Nokia Oyj Sponsored ADR (NOK.US) fell over 9%.
CNBM (03323): Beijing New Building Materials Public (000786.SZ) reported a net profit attributable to shareholders of RMB 1.905 billion for the first three quarters, down 26.35% year on year.
